Patents by Inventor Andrew Stott

Andrew Stott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterobicyclic amides as inhibitors of CD38
    Publication number: 20260224582
    Abstract: The present invention provides compounds of formula (I): 5 A 1 X Y N R 2 R 1 A 2 A 3 A 4 n Formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein R1, R2, n, A1, A2, A3, A4, X and Y are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly for 10 use in treating disorders associated with CD38 activity.
    Type: Application
    Filed: May 18, 2023
    Publication date: August 6, 2026
    Applicant: Cerevance, Inc.
    Inventors: Roland Burli, Kevin Doyle, Andrew Stott
  • HTT modulators for treating Huntington's disease
    Patent number: 12281116
    Abstract: Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: April 22, 2025
    Assignee: CHDI Foundation, Inc.
    Inventors: Longbin Liu, Celia Dominguez, Nikolay V. Plotnikov, Alan Haughan, Andrew Stott, Brett Cosgrove, Cole Clissold, Huw Vater, Jonathan Spencer, William Esmieu, Karine Malagu, Mark Chambers
  • HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20230159531
    Abstract: Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.
    Type: Application
    Filed: November 16, 2022
    Publication date: May 25, 2023
    Inventors: Longbin Liu, Celia Dominguez, Nikolay V. Plotnikov, Alan Haughan, Andrew Stott, Brett Cosgrove, Cole Clissold, Huw Vater, Jonathan Spencer, William Esmieu, Karine Malagu, Mark Chambers